Skip to main content
. 2021 Feb 19;12:551975. doi: 10.3389/fneur.2021.551975

Table 1.

Baseline sample size for each AD marker in the overall and MCI subsample as a function of sex and prediabetes status.

Diagnostic Group/AD marker Total Sample, N Maximum follow-up period examined (months) Women Men
Prediabetic, N Normo-glycemic, N Prediabetic, N Normo-glycemic, N
Overall
    HV/IV 803 36 154 222 194 233
    CMRglu 911 72 167 252 222 270
    p-tau181/Aβ1−42 ratio 718 48 134 206 172 206
    AVLT Z-scores 910 60 167 251 222 270
    TMT Part B Z-scores 902 60 165 249 219 269
    BNT Z-scores 910 60 167 251 222 270
    Incident dementia 850 All available 154 239 203 254
    analysis*
MCI
    HV/IV 330 24 50 89 98 93
    CMRglu 354 36 58 104 81 111
    p-tau181/Aβ1−42 ratio 290 48 46 88 76 80
    AVLT Z-scores 370 48 58 103 98 111
    TMT Par B Z-scores 368 48 58 103 96 111
    BNT Z-scores 370 48 58 103 98 111
    Incident dementia 341 all available 55 96 87 103
    analysis*
*

Cox proportional hazards models estimating incident dementia rates were conducted in participants with at-least one follow-up visit. MCI, Mild Cognitive Impairment; HV/IV, hippocampal/intracranial volume x 103; CMRGlu, cerebral metabolic glucose rate; p-tau181/Aβ1-42, phosphorylated tau/amyloid-β; AVLT, Rey Auditory Verbal Learning Test; TMT, Trail Making Test; BNT, Boston Naming Test.